User:Mr. Ibrahem/Belzutifan

Belzutifan, sold under the brand name Welireg, is a medication used to treat von Hippel–Lindau disease-associated renal cell carcinoma, central nervous system (CNS) hemangioblastoma, or pancreatic neuroendocrine tumor (pNET). It is taken by mouth.

Common side effects include low hemoglobin, tiredness, kidney problems, headache, dizziness, increased blood sugar, and nausea. Other side effects may include low oxygen. Use during pregnancy may harm the baby. It is an hypoxia-inducible factor 2α inhibitor.

Belzutifan was approved for medical use in the United States in 2021. In the United Kingdom a month of treatment costs the NHS about £12,000 as of 2022. This amount in the United States costs about 28,000 USD. It is not yet available in Europe.